GLP-1 industry news
Dated developments affecting what a GLP-1 costs and who sells it. Every item carries the date of the development rather than the date we wrote about it, and closes on what it changes for someone paying for treatment.
Every story, newest first
Novo cuts self-pay pen pricing to about $349 a month
Direct cash pricing for the branded semaglutide pen falls far below list, narrowing the gap compounded programmes have relied on s
Medicare access expands to a flat monthly co-pay
Eligible Part D beneficiaries gain a route that undercuts every compounded programme we track.
FDA proposes excluding GLP-1s from the 503B bulks list
If finalised, outsourcing facilities would lose the pathway for compounding these molecules at scale.
Alerts continue on counterfeit product and unapproved salt for
Two different problems with one outcome: an unverified substance in a syringe.
Generic semaglutide launches in India and Canada
Patents lapsed across roughly ten markets in 2026. US patents run into the early 2030s.
Hims closes its compounded GLP-1 programme to new patients
Following a settlement with Novo Nordisk, one of the largest consumer platforms exits compounded semaglutide.
Zepbound self-pay pricing set at $299 to $449 by dose
The starter dose drops to $299 and higher doses to $449, on a 45-day refill condition most coverage omits.
Oral semaglutide launches for weight management at about $149
An FDA-approved tablet reaches the market inside the compounded price band, removing the main reason many patients took the compou
FDA issues more than 55 warning letters to online GLP-1 seller
The agency targeted direct-to-consumer advertising by compounded GLP-1 marketers rather than product quality.
FDA declares the semaglutide shortage resolved
The declaration narrowed lawful compounding to the patient-specific 503A pathway and set the deadlines that reshaped the market.